Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-004: MK-1084 plus pembrolizumab vs pembrolizumab for first-line KRAS G12C-mutant NSCLC with high PD-L1
jRCT2031240213Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-1084 + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240213.